EP-300 target protein degrader ( Foghorn Therapeutics)

N/A

Report date: 2025/05/20 15:00:30
NME

Base Information

Drug NameEP-300 target protein degrader ( Foghorn Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionHistone acetyltransferase p300 degraders
TargetsHistone acetyltransferase p300
Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFoghorn Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFoghorn Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A